Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B
- PMID: 17657598
- DOI: 10.1007/s11095-007-9302-8
Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B
Abstract
Purpose: To investigate the use of poly (lactide-co-glycolide) (PLGA) microparticles in respirable sizes as carriers for Antigen 85B (Ag85B), a secreted protein of Mycobacterium tuberculosis, with the ultimate goal of employing them in pulmonary delivery of tuberculosis vaccine.
Materials and methods: Recombinant Ag85B was expressed from two Escherichia coli strains and encapsulated by spray-drying in PLGA microspheres with/without adjuvants. These microspheres containing rAg85B were assessed for their ability to deliver antigen to macrophages for subsequent processing and presentation to the specific CD4 T-hybridoma cells DB-1. DB-1 cells recognize the Ag85B(97-112) epitope presented in the context of MHC class II and secrete IL-2 as the cytokine marker.
Results: Microspheres suitable for aerosol delivery to the lungs (3.4-4.3 microm median diameter) and targeting alveolar macrophages were manufactured. THP-1 macrophage-like cells exposed with PLGA-rAg85B microspheres induced the DB-1 cells to produce IL-2 at a level that was two orders of magnitude larger than the response elicited by soluble rAg85B. This formulation demonstrated extended epitope presentation.
Conclusions: PLGA microspheres in respirable sizes were effective in delivering rAg85B in an immunologically relevant manner to macrophages. These results are a foundation for further investigation into the potential use of PLGA particles for delivery of vaccines to prevent M. tuberculosis infection.
Similar articles
-
PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B.Pharm Res. 2010 Feb;27(2):350-60. doi: 10.1007/s11095-009-0028-7. Epub 2009 Dec 19. Pharm Res. 2010. PMID: 20024670
-
Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system.Vaccine. 2013 Jan 21;31(5):784-90. doi: 10.1016/j.vaccine.2012.11.075. Epub 2012 Dec 7. Vaccine. 2013. PMID: 23228812
-
Recombinant Bacillus subtilis spores for the delivery of Mycobacterium tuberculosis Ag85B-CFP10 secretory antigens.Tuberculosis (Edinb). 2016 Dec;101S:S18-S27. doi: 10.1016/j.tube.2016.09.016. Epub 2016 Sep 28. Tuberculosis (Edinb). 2016. PMID: 27727129
-
Formulating poly(lactide-co-glycolide) particles for plasmid DNA delivery.J Pharm Sci. 2008 Jul;97(7):2448-61. doi: 10.1002/jps.21215. J Pharm Sci. 2008. PMID: 17918737 Review.
-
Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems.Curr Drug Deliv. 2006 Jan;3(1):115-20. doi: 10.2174/156720106775197565. Curr Drug Deliv. 2006. PMID: 16472100 Review.
Cited by
-
CFP10-loaded PLGA nanoparticles as a booster vaccine confer protective immunity against Mycobacterium bovis.Bioimpacts. 2022;12(5):395-404. doi: 10.34172/bi.2022.23645. Epub 2022 Jun 8. Bioimpacts. 2022. PMID: 36381632 Free PMC article.
-
Pharmaceutical aerosols for the treatment and prevention of tuberculosis.Front Cell Infect Microbiol. 2012 Sep 7;2:118. doi: 10.3389/fcimb.2012.00118. eCollection 2012. Front Cell Infect Microbiol. 2012. PMID: 22973562 Free PMC article. Review.
-
Rational design of multiple TB antigens TB10.4 and TB10.4-Ag85B as subunit vaccine candidates against Mycobacterium tuberculosis.Pharm Res. 2010 Feb;27(2):224-34. doi: 10.1007/s11095-009-9995-y. Epub 2009 Oct 28. Pharm Res. 2010. PMID: 19862606
-
Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy.Front Immunol. 2019 Apr 5;10:707. doi: 10.3389/fimmu.2019.00707. eCollection 2019. Front Immunol. 2019. PMID: 31024545 Free PMC article. Review.
-
Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy.Expert Opin Drug Deliv. 2012 May;9(5):541-50. doi: 10.1517/17425247.2012.676038. Epub 2012 Apr 5. Expert Opin Drug Deliv. 2012. PMID: 22475249 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous